Under construction – not a live service
Sign in
Not yet taking people in GermanyNo phase

A Digital Remote Monitoring App for People With Transthyretin Amyloid Cardiomyopathy

Looks at how acceptable and practical the Luscii monitoring tool is for adults with ATTR-CM.

Key facts

Who runs it
Bayer
Where
Heidelberg, GermanySee the siteAlso in 2 other countries, 2 sites
Trial code
Registry title
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor
Status
Not yet recruiting
People taking part
60 people, planned
Started
30 Oct 2026
Expected to end
15 May 2028
Type of study
Observational
Treatments tested
  • Luscii
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with wild-type or variant ATTR-CM who are on an approved drug for it and can use a smartphone app. Doctors who treat them can also join.

Age
18 years or older
Sex
All sexes
Disease stage
Wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy (ATTR-CM)
Earlier treatment
Treatment with a drug approved for ATTR-CM, including a newly prescribed therapy at the first visit

Main reasons for not taking part

  • Taking part in an investigational program with interventions outside of routine clinical practice
  • Cannot give consent themselves, for example when a legal representative would need to consent
  • No personal smartphone with enough internet to run the Luscii contact app
  • Doctors currently affiliated with Luscii, Bayer or their affiliates cannot join

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • For patients:
  • Adult (≥18 years at the date of signing the informed consent form (ICF))
  • Diagnosis of either wild-type or variant ATTR-CM
  • Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit
  • Signed ICF
  • Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application; For medical professionals:
  • Directly involved in the treatment or clinical management of the enrolled ATTR-CM participants and having access to and reviewing the Luscii-captured data for routine care
  • Agreement to ICF within the EDC system for the purpose of using Luscii or to complete the HCP Experience Questionnaire

Who cannot take part

  • For patients:
  • Participation in an investigational program with interventions outside of routine clinical practice
  • Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative; For medical professionals:
  • Any current affiliation with Luscii, Bayer, or any of their affiliates

Where in Germany

Also in 2 other countries, 2 sites

  • Universitätsklinikum HeidelbergHeidelberg, GermanyNo longer taking part

About the trial

What the trial wants to find out

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.

Read full original descriptionShow less

People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.

Remote monitoring offers a way for people living with ATTR-CM and their healthcare professionals to stay connected between clinic visits. Recent studies have shown that remote monitoring can help by making it easier to share health information, spot problems earlier, and support people to follow their treatment plans. This can lead to fewer hospital visits and better health outcomes.

Luscii is a digital remote monitoring tool designed to help people living with ATTR-CM and their healthcare professionals stay connected between clinic visits. Luscii has two main parts: Luscii contact, a smartphone app that allows secure messaging and video calls, and Luscii vitals, a clinical software system that organizes health data and can alert the healthcare team if there are changes that need attention. Luscii vitals is a CE-marked medical device used within its approved purpose and does not replace a doctor's judgement.

By making it easier to communicate and share information, Luscii aims to support earlier detection of problems, better management of ATTR-CM, and a more positive experience for people living with this condition.

The main purpose of this observational study, called ACO-MONITOR, is to learn how acceptable and practical Luscii is for people living with ATTR-CM and their healthcare professionals. The study will take place in Austria, Germany, and Italy at three specialist centers. About 60 adults with a diagnosis of hereditary or wild-type ATTR-CM will be invited to take part. There will be no treatments given as part of this study. Instead, participants will use the Luscii app and devices at home to track their health and share information with their healthcare professionals. The study team will provide training on how to use Luscii and will help participants get started.

The study team will look at:

* How quickly and how often participants and healthcare professionals use Luscii * How long Luscii is used by each person * How many times participants use Luscii after being reminded * How easy Luscii is to use, based on questionnaires for both participants and healthcare professionals

The study will last about 18 months in total, including a 6-month period to invite participants and a 12-month follow-up period. During the study, the study team will:

* Support participants in using Luscii to share health information from home * Monitor how often and how easily Luscii is used * Ask participants and healthcare professionals about their experiences using Luscii, including what worked well and what could be improved * Record any problems or technical issues with using Luscii By collecting this information, the researchers hope to learn if Luscii can help improve communication, support earlier detection of health problems, and make it easier for people living with ATTR-CM to manage their condition between clinic visits.

The group in the trial

  • Wild-type or variant ATTR-CM participants

    Participants will be enrolled after the decision to initiate the use of the digital remote monitoring tool, Luscii, as per standard use.

    Treatment: Luscii

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Observational Study to Learn More About How Acceptable and Practical a Digital Remote Monitoring Tool (Luscii) is in People With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Plain-language title
A Digital Remote Monitoring App for People With Transthyretin Amyloid CardiomyopathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 October 2026